Cardiff Oncology Director PACE GARY W buys 275,000 shares at $2.45/share on July 30.

Cardiff Oncology, Inc. (CRDF) has announced that Director Gary W. PACE has made a significant investment in the company. On July 30, 2025, Director PACE acquired 275,000 shares at a price of $2.45 per share. Additionally, Director PACE also purchased an additional 15,000 shares at the same price on the same day. These transactions demonstrate Director PACE's confidence in the company's future prospects and his commitment to its success.

Cardiff Oncology, Inc. (CRDF) has seen a significant increase in share price following a substantial investment by Director Gary W. PACE. On July 30, 2025, Director PACE acquired 275,000 shares at a price of $2.45 per share. Additionally, he purchased an extra 15,000 shares at the same price on the same day. These transactions indicate Director PACE's confidence in the company's future prospects and his commitment to its success.

The share price of Cardiff Oncology, Inc. (CRDF) has been volatile in recent months. The company recently released data from its Phase 2 clinical trial, CRDF-004, which evaluated onvansertib in combination with standard-of-care (SoC) for first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated promising results, with an overall objective response rate (ORR) of 59% in the high-dose arm and 50% in the 20mg dose arm compared to a 43% response rate in the control arm [1].

The confirmed ORRs at 6 months were 49% for the high-dose arm, 42% for the low-dose arm, and 30% for the control arm. The data also showed that the 30mg dose of onvansertib combined with SoC resulted in deeper responses and an early separation of the progression-free survival (PFS) curves compared to the control arm and the 20mg dose arm [1].

The safety analysis of the trial, which included 104 patients, indicated that onvansertib was well-tolerated with no major or unexpected toxicities. The most common treatment-emergent adverse event associated with onvansertib was neutropenia [1].

Analysts have expressed differing views on the potential impact of these results. While some analysts like Andy Hsieh have noted considerable skepticism regarding the compound's clinical profile, others such as William Blair hold a bullish view that onvansertib could potentially disrupt the RAS-mutated frontline mCRC treatment paradigm [1].

The latest data from Cardiff Oncology, Inc. (CRDF) indicates that the company is making progress in its efforts to develop effective treatments for metastatic colorectal cancer. Director PACE's investment in the company reflects his optimism about its future prospects and the potential of onvansertib to improve patient outcomes.

References:
[1] https://www.inkl.com/news/why-is-cardiff-oncology-stock-trading-lower-after-colorectal-cancer-data